A Physiological Prophylaxis of Deep Venous Thrombosis in Arthroplasty: A Prospective Study
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 5, Pages 146-152
AbstractBackground: A potentially lethal condition is known as venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis (DVT). To determine the effectiveness of pharmacological prophylaxis against PE or DVT (Pulmonary Embolism). To ascertain the prevalence of DVT (Deep Venous Thrombosis) or PE (Pulmonary Embolism) despite prevention. On the subject, relatively few studies from India have been published, and nothing is known about the true prevalence of the disorder. Due to a sharp rise in the number of joint replacement surgeries, the topic has recently taken on more importance among Indian people. Regarding the prophylaxis for VTE in Indian patients, there are no precise recommendations.
Materials and Methods: In order to investigate the prevalence of DVT, we designed and carried out a prospective study. The current study comprised a total of fifty patients who had undergone THR, TKR, or HRA. The duplex ultra-sonography was performed on each of the patients between the seventh day and the third week of postoperative day. As a preventative measure against deep vein thrombosis (DVT), all patients received subcutaneous Enoxaparin 40 mg once day for 5 days and Asprin for 4 weeks.
Results: Only two patients or four percent of the total, revealed sonographic evidence of distal asymptomatic DVT, and both of those patients' symptoms went away on their own without any treatment. During the follow-up scan, there was no evidence of proximal DVT propagation, and there were also no incidences of pulmonary embolism.
Conclusion: DVT in patients who have undergone THR, TKR, or HRA is not nearly as common as it is reported to be in the Western medical literature. It is essential to maintain a high level of suspicion, in addition to close clinical surveillance. In our society, deep vein thrombosis (DVT) is hardly an unheard-of condition. Although low molecular weight heparin is a safe medicine, it appears that the risk of bleeding problems is higher than what is described in Western medical literature. In the future, it will be necessary to conduct additional trials that involve a greater number of patients and take place at many centres in order to corroborate the findings of our study and evaluate the actual efficacy and safety of LMWH.
- Article View: 7
- PDF Download: 14